Literature DB >> 17575270

Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.

Eugenia Nikolsky1, Roxana Mehran, George Dangas, Martin Fahy, Yingbo Na, Stuart J Pocock, A Michael Lincoff, Gregg W Stone.   

Abstract

AIMS: Major bleeding after percutaneous coronary intervention (PCI) is an independent risk factor for early and late mortality. We developed and validated a risk score predictive of major bleeding after PCI using the femoral approach. METHODS AND
RESULTS: Baseline clinical and procedural variables from two contemporary, multicentre, randomized PCI trials were used for risk score development (the REPLACE-2 trial, n = 6002) and validation (the REPLACE-1 trial, n = 1056). On the basis of the odds ratio, independent risk factors were assigned a weighted integer, the sum of which comprised a total risk score. Seven variables were identified as independent correlates of major bleeding (age >55 years, female gender, estimated glomerular filtration rate <60 mL/min/1.73 m(2), pre-existing anaemia, administration of low-molecular-weight heparin within 48 h pre-PCI, use of glycoprotein IIb/IIIa inhibitors, and intraaortic balloon pump use). In the development set, the risk of major bleeding varied from 1.0% in patients without risk factors to 5.4% in high-risk patients. The discriminatory power of this risk model was confirmed in the validation data set (area under the receiver operating curve = 0.62).
CONCLUSION: A simple risk score of baseline clinical and procedural variables is useful to predict the incidence of major peri-procedural bleeding after contemporary PCI using the femoral approach.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575270     DOI: 10.1093/eurheartj/ehm194

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  36 in total

1.  'Ins' and 'outs' of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting.

Authors:  W Dewilde; F W A Verheugt; N Breet; J J Koolen; J M Ten Berg
Journal:  Neth Heart J       Date:  2010-09       Impact factor: 2.380

Review 2.  Bioresorbable Scaffolds: Current Evidences in the Treatment of Coronary Artery Disease.

Authors:  Bhargav Dave
Journal:  J Clin Diagn Res       Date:  2016-10-01

3.  BLEED-Myocardial Infarction Score: Predicting mid-term post-discharge bleeding events.

Authors:  Sérgio Barra; Rui Providência; Francisca Caetano; Inês Almeida; Luís Paiva; Paulo Dinis; António Leitão Marques
Journal:  World J Cardiol       Date:  2013-06-26

4.  Bivalirudin for patients with STEMI at high risk of bleeding undergoing PPCI.

Authors:  Lu Hu; Kai Guo; Zhigang Guo
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

5.  The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders.

Authors:  Muhammad Ali Khan; Colin W Howden
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

6.  Risk factors for nosocomial gastrointestinal bleeding and use of acid-suppressive medication in non-critically ill patients.

Authors:  Shoshana J Herzig; Michael B Rothberg; David B Feinbloom; Michael D Howell; Kalon K L Ho; Long H Ngo; Edward R Marcantonio
Journal:  J Gen Intern Med       Date:  2013-01-05       Impact factor: 5.128

7.  Transradial approach as a default route in coronary artery interventions.

Authors:  Jang-Young Kim; Junghan Yoon
Journal:  Korean Circ J       Date:  2011-01-31       Impact factor: 3.243

8.  The bleeding risk score as a mortality predictor in patients with acute coronary syndrome.

Authors:  José Carlos Nicolau; Humberto Graner Moreira; Luciano Moreira Baracioli; Carlos Vicente Serrano; Felipe Galego Lima; Marcelo Franken; Roberto Rocha Giraldez; Fernando Ganem; Roberto Kalil Filho; José Antônio Franchini Ramires; Roxana Mehran
Journal:  Arq Bras Cardiol       Date:  2013-11-12       Impact factor: 2.000

9.  Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis.

Authors:  Gregory Ducrocq; Joshua S Wallace; Gabriel Baron; Philippe Ravaud; Mark J Alberts; Peter W F Wilson; Erik Magnus Ohman; Danielle M Brennan; Ralph B D'Agostino; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Eur Heart J       Date:  2010-02-24       Impact factor: 29.983

10.  Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents.

Authors:  L Testa; G G L Biondi Zoccai; M Valgimigli; R A Latini; S Pizzocri; S Lanotte; M L Laudisa; N Brambilla; M R Ward; G A Figtree; F Bedogni; R Bhindi
Journal:  Adv Hematol       Date:  2010-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.